Results 51 to 60 of about 274,774 (268)

Trial watch: DNA-based vaccines for oncological indications

OncoImmunology, 2017
DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated.
Stefano Pierini, Renzo Perales-Linares, Mireia Uribe-Herranz, Jonathan G. Pol, Laurence Zitvogel, Guido Kroemer, Andrea Facciabene, Lorenzo Galluzzi   +7 more
doaj   +1 more source

Expanding Chemical Space of Nucleic Acid Nanoparticles for Tunable Antiviral‐Like Immunomodulatory Responses and Potent Adjuvant Activity

Advanced Functional Materials, EarlyView.
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj, Hannah S. Newton, Jian Wang, Laxmi Pandey, Yelixza I. Avilla, Phong Nguyen, Morgan Chandler, Justin Halman, Yasmine Radwan, Stephanie Smith, Elijah Edmondson, Simone Difilippantonio, Chelsea Sanders, Bao Tran, Yongmei Zhao, Shaojun Xie, Edward Cedrone, Barry W. Neun, Meni Wanunu, Nikolay V. Dokholyan, Marina A. Dobrovolskaia, Kirill A. Afonin   +21 more
wiley   +1 more source

Improved DNA Vaccine Delivery with Needle-Free Injection Systems

Vaccines, 2023
DNA vaccines have inherent advantages compared to other vaccine types, including safety, rapid design and construction, ease and speed to manufacture, and thermostability.
Carmen Ledesma-Feliciano, Ros Chapman, Jay W. Hooper, Kira Elma, Darin Zehrung, Miles B. Brennan, Erin K. Spiegel   +6 more
doaj   +1 more source

A Potent and Effective Suicidal Listeria Vaccine Platform. [PDF]

, 2019
Live-attenuated Listeria monocytogenes has shown encouraging potential as an immunotherapy platform in preclinical and clinical settings. However, additional safety measures will enable application across malignant and infectious diseases.
Benanti, Erin L, Brockstedt, Dirk G, Chen, Chen, Dubensky, Thomas W, Fassò, Marcella, Hanson, William G, Lauer, Peter, Lemmens, Edward E, Leong, Meredith L, Liu, Weiqun, Portnoy, Daniel A, Rae, Chris S, Skoble, Justin   +12 more
core  

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source

Programmable DNA‐Peptide Hybrid Nanostructures for Potent Neutralization of Multiple Influenza a Virus Subtypes

Advanced Functional Materials, EarlyView.
A multivalent antiviral platform based on honeycomb‐shaped DNA nanostructures (HC–Urumin) is developed to enhance the potency and breadth of the host defense peptide Urumin. Through spatially patterned trimeric presentation, HC–Urumin disrupts influenza A virus entry, improves cell viability, and reduces disease severity in vivo‐offering a modular and ...
Saurabh Umrao, Abhisek Dwivedy, Payton L. Haak, Dhanush Gandavadi, Laurie A. Rund, Chi Chen, Vineetha Mareddy, Lifeng Zhou, Jinwei Duan, Ying Fang, Andrew J. Steelman, Xing Wang   +11 more
wiley   +1 more source

Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now [PDF]

, 2015
Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver
Cuestas, María Luján, Eguibar, Nair, Gonzalez, Rodrigo Horacio, Nusblat, Alejandro David, Perazzo, Priscila   +4 more
core   +1 more source

Bimetallic Nanoreactor Activates cGAS‐STING Pathway via mtDNA Release for Cancer Metalloimmunotherapy

Advanced Functional Materials, EarlyView.
A bimetallic Mn–Ca nanoreactor (MCC) is developed as a non‐nucleotide STING nanoagonist for cancer metalloimmunotherapy. MCC induces Ca2+ overload and hydroxyl radical generation, resulting in mitochondrial damage and mtDNA release. The released mtDNA cooperates with Mn2+ to robustly activate cGAS–STING signaling.
Xin Wang Mo, Nguyen Thi Nguyen, LiLi Guo, Ngoc Man Phan, Hyunsu Shin, Tae‐il Kim, Yu Seok Youn, Jaeyun Kim   +7 more
wiley   +1 more source

New insights for the development of efficient DNA vaccines

Microbial Biotechnology
Despite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical ...
Simone Berger, Yanira Zeyn, Ernst Wagner, Matthias Bros   +3 more
doaj   +1 more source

Adjuvants : an essential component of neisseria vaccines [PDF]

, 2009
Adjuvants may be classified into delivery systems and immune potentiator or modulator molecules based on their mechanism of action. Neisseria vaccines containing traditional adjuvants such as aluminium salts have existed for long time, but meningitis ...
Acevedo, R., Balbao, J., Cabrera, O., Cuello, M., del Campo, J., Ferro, Valerie A., Gonzales, E., Romeu, B., Zayas, C.   +8 more
core